Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing.

Journal article

Hanson B. et al, (2021), RNA Biol, 1 - 15

Application of CRISPR-Cas9-Mediated Genome Editing for the Treatment of Myotonic Dystrophy Type 1.

Journal article

Marsh S. et al, (2020), Mol Ther, 28, 2527 - 2539

Mutation-independent Proteomic Signatures of Pathological Progression in Murine Models of Duchenne Muscular Dystrophy.

Journal article

van Westering TLE. et al, (2020), Mol Cell Proteomics, 19, 2047 - 2068

Advances in oligonucleotide drug delivery.

Journal article

Roberts TC. et al, (2020), Nat Rev Drug Discov, 19, 673 - 694

Uniform sarcolemmal dystrophin expression is required to prevent extracellular microRNA release and improve dystrophic pathology.

Journal article

van Westering TLE. et al, (2020), J Cachexia Sarcopenia Muscle, 11, 578 - 593

The viral protein corona directs viral pathogenesis and amyloid aggregation.

Journal article

Ezzat K. et al, (2019), Nat Commun, 10

MINCR is not a MYC-induced lncRNA.

Journal article

Hart JR. et al, (2016), Proc Natl Acad Sci U S A, 113, E496 - E497

The Bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation.

Journal article

Pastori C. et al, (2015), Proc Natl Acad Sci U S A, 112, 8326 - 8331

HIV Latency and the noncoding RNA therapeutic landscape.

Chapter

Saayman S. et al, (2015), 848, 169 - 189

LEPIGENETIC MYOSTATIN BLOCKADE

Conference paper

Roberts T. et al, (2011), NUCLEIC ACID THERAPEUTICS, 21, A24 - A24